Premium
The canine prostate cancer cell line CHP‐1 shows over‐expression of the co‐chaperone small glutamine‐rich tetratricopeptide repeat‐containing protein α
Author(s) -
Azakami D.,
Nakahira R.,
Kato Y.,
Michishita M.,
Kobayashi M.,
Onozawa E.,
Bonkobara M.,
Kobayashi M.,
Takahashi K.,
Watanabe M.,
Ishioka K.,
Sako T.,
Ochiai K.,
Omi T.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12199
Subject(s) - tetratricopeptide , prostate cancer , androgen receptor , androgen , cancer research , dihydrotestosterone , prostate , biology , medicine , cancer , chemistry , biochemistry , hormone , gene
Although androgen therapy resistance and poor clinical outcomes are seen in most canine prostate cancer cases, there are only a few tools for analysing canine prostate cancer by using a cell biological approach. Therefore, to evaluate androgen‐independent neoplastic cell growth, a new canine prostate cancer cell line ( CHP ‐1) was established in this study. CHP ‐1 over‐expressed the co‐chaperone small glutamine‐rich tetratricopeptide repeat‐containing protein α ( SGTA ), which is over‐expressed in human androgen‐independent prostate cancer. The CHP ‐1 xenograft also showed SGTA over‐expression. Although CHP ‐1 shows poor androgen receptor ( AR ) signalling upon dihydrotestosterone stimulation, forced expression of AR enabled evaluation of AR signalling. Taken together, these results suggest that CHP ‐1 will be a useful model for investigating the pathogenesis of androgen‐dependent and androgen‐independent canine prostate cancer.